Gene therapy for hemophilia seeks sustained endogenous production of coagulation factor VIII (FVIII) or factor IX (FIX) after a single administration, most commonly through liver-directed adeno-associated virus (AAV) delivery. The field provides clinical proof that modest factor expression can reduce bleeding, but it also exposes challenges in patient selection, immune management, manufacturing, durability, and long-term safety.
